மையம் க்கு வணிகமயமாக்கல் ஆஃப் மீளுருவாக்கம் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AVECTAS Leads €7.23 million Consortium Awarded Part Funding From Ireland’s Disruptive Technologies Innovation Fund Funding to develop high throughput cell engineering technology to manufacture off the shelf cell therapies Project, led by Avectas in partnership with Bluebridge Technologies and National Institute for Bioprocessing Research and Training (NIBRT), would support Ireland s goal of being at the forefront of cell therapy manufacturing Kildare, Ireland and Cambridge, MA, USA … Friday 23 April 2021.  Irish cell engineering company, Avectas, is leading a consortium which will invest €7.23 million, including €4.4 million awarded under the Irish Government’s Disruptive Technology Innovation Fund (DTIF), to develop a high-throughput scale of its proprietary cell engineering platform Solupore®. With consortium partners Bluebridge Technologies and NIBRT, the project expands Avectas development towards commercialising an advanced large-scale, digitalised cell engin

United statesUnited kingdomNiall barronMichael maguireGarret coadySimon laboratoryDepartment of enterpriseIrish government disruptive technology innovation fundEuropean unionCentre for commercialization of regenerative medicineDisruptive technologies innovation fundIrish governmentDisruptive technology innovation fundBluebridge technologiesProject irelandEnterprise trade